alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 376–400 of 504 studies in Mild cognitive impairment · free to read (page 16 of 21) · 30,980 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,452 studies have no institution on record and are not counted here.

What “Mild cognitive impairment” covers

Mild cognitive impairment — The stage between normal ageing and dementia: who progresses, who doesn't, and what predicts it.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Screening tools for subjective cognitive decline and mild cognitive impairment based on task-state prefrontal functional connectivity: a functional near-infrared spectroscopy study

✓ Peer-reviewed alzhub usefulness score 45 out of 100. NeuroImage 2025-03-07

Statistical analysis revealed a trend toward more impaired prefrontal FC with declining cognitive function. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mild cognitive impairment and neuropsychological examination

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Frontiers in Psychology 2025-11-06

The paper discusses according to prevailing diagnostic systems and algorithms, which cognitive domains that are relevant to investigate, which tests that may be relevant, what kind of norms have satisfactory quality, which cut-off scores do best balance sensitivity and specificity in a neurodiagnostic context, and what kind of conclusions and recommendations that can be drawn from neuropsychological findings. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Real-world health care costs and resource utilization associated with mild cognitive impairment in the United States: A retrospective cohort study of commercial and Medicare data

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of Managed Care & Specialty Pharmacy 2025-07-24

< 0.0001) were significantly higher for the MCI cohort. 3 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of neuroinflammation 2016-08-24

Our current studies indicate that thrombin and HMGB1 are causal proximate proinflammatory mediators of BBB dysfunction, while sTM levels may indicate BBB endothelial damage; HMGB1 and sRAGE might serve as clinical biomarkers for progression and/or therapeutic efficacy along the AD spectrum. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: Insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodegeneration in a prodromal stage of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of neuroscience research 2010-02-01

Alzheimer's disease (AD) is the most common form of dementia and is pathologically characterized by senile plaques, neurofibrillary tangles, synaptic disruption and loss, and progressive neuronal deficits. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Abnormal insula functional network is associated with episodic memory decline in amnestic mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 44 out of 100. NeuroImage 2012-07-06

Abnormalities of functional connectivity in the default mode network (DMN) recently have been reported in patients with amnestic mild cognitive impairment (aMCI), Alzheimer's disease (AD) or other psychiatric diseases. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Progression of mild cognitive impairment to dementia: a challenge to current thinking

✓ Peer-reviewed alzhub usefulness score 44 out of 100. The British journal of psychiatry : the journal of mental science 2006-11-01

Further long-term studies are needed to examine the time-dependent evolution from mild cognitive impairment to dementia and to establish age-specific conversion rates during lifetime. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Antioxidants & redox signaling 2010-03-01

Previous studies indicated increased levels of protein oxidation in brain from subjects with Alzheimer's disease (AD), raising the question of whether oxidative damage is a late effect of neurodegeneration or precedes and contributes to the pathogenesis of AD. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Allostatic load dynamics, Alzheimer's disease biomarkers, and progression in individuals with mild cognitive impairment: findings from the Alzheimer's Disease Neuroimaging Initiative

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2025-07-01

A one‐point ALI increase was associated with MCI conversion odds by 15%. 1 key finding →

Participants: 385 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Talking during walking: the diagnostic potential of turn dynamics in Alzheimer’s disease, mild cognitive impairment and cognitive aging

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Frontiers in Aging Neuroscience 2025-02-19

-values compared to gait features. Linear regression analysis indicated that turn dynamics had stronger correlations with executive function and working memory, suggesting a more pronounced relationship between cognitive performance and turn features than gait variables. 3 key findings →

Participants: 75 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Changes in the Parietal Lobe Subregion Volume at Various Stages of Alzheimer’s Disease and the Role in Cognitively Normal and Mild Cognitive Impairment Conversion

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of Integrative Neuroscience 2025-01-21

The left inferior parietal lobule (IPL)_6_5 (rostroventral area 39) showed the best ability to discriminate between patients with AD and those with CN (AUC = 0.688). 5 key findings →

Participants: 662 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Inequalities in Mild Cognitive Impairment Risk Among Chinese Middle-Aged and Older Adults: Insights from an Integrated Learning Model

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Risk Management and Healthcare Policy 2025-06-01

The CNN-BiLSTM-Attention model demonstrated relatively promising predictive performance (AUC: 0.7317), with moderately high sensitivity (0.6902) and a high negative predictive value (NPV) of 0.9414. 5 key findings →

Participants: 4,626 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Role of visual function and performance of activities of daily living in cognitive function in patients with mild cognitive impairment: a cross-sectional study

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Frontiers in Aging Neuroscience 2025-02-05

These findings suggest that visual function plays a crucial role in the cognitive and functional abilities of patients with MCI. 2 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Characterizing bidirectional transitions in mild cognitive impairment and post‐reversion based on longitudinal neuroimaging and cognitive assessments

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Alzheimer s & Dementia 2025-05-01

The probability of reversion increased from 2% at baseline to a maximum of 8% by year 10 before gradual decline thereafter. 5 key findings →

Design: retrospective cohort Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cardiometabolic disorders and mild cognitive impairment in White and Black Americans

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Alzheimer s & Dementia 2025-09-01

Controlling for demographic/health variables, individuals with aMCI, though not naMCI, showed a higher likelihood of hypertension, diabetes, and hyperlipidemia compared to cognitively normal counterparts, though no differences between aMCI/naMCI. 5 key findings →

Participants: 8,737 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Towards the development of a management protocol for subjective cognitive decline: Insights from a cross-sectional and longitudinal analysis of multimodal data from a memory clinic

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of Alzheimer s Disease 2026-01-28

This study highlights the role of age, gender, APOE genotype, and depressive symptoms in the presentation and progression of cognitive decline. 2 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Combining EEG, event-related potentials, and MRI biomarkers for detection of mild cognitive impairment: A machine learning approach

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Clinical Neurophysiology 2026-05-06

EEG/ERP analysis suggested differences in frontal alpha asymmetry, power ratio, and ERP components between the MCI and CN groups. 5 key findings →

Participants: 70 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

What Does a Positive Alzheimer Disease Blood-Based Biomarker Result Mean in People With Mild Cognitive Impairment?

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Neurology 2026-05-04

Blood-based biomarkers (BBMs) for Alzheimer disease (AD) offer widely expanded access to biomarker-informed diagnoses in community settings that have previously lacked such resources. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Diagnostic value and difference of quantitative susceptibility mapping and voxel-based morphological analysis in patients with Alzheimer’s disease and mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Chinese Medical Journal 2025-07-17

To the Editor: With the aging of the population, the prevalence of Alzheimer’s disease (AD) has increased significantly. 5 key findings →

Design: longitudinal study Participants: 20 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events